MetaCap

Caris Life Sciences (CAI) vs Celcuity (CELC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Caris Life Sciences (CAI) has outperformed Celcuity (CELC) over the past year, losing 27.0% versus a loss of 45.3%. Caris Life Sciences is the larger company by market cap ($5.04 billion vs $2.61 billion), about 1.9 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CAI-27.02%CELC-45.28%
+55%+2%-50%
Nov 21, 20251 yearNov 20, 2026
CAI-35.49%CELC+359.91%
+1149%+523%-104%
Jun 16, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CAI versus CELC key metrics
MetricCAICELC
Share price$17.58$53.35
Market cap$5.04B$2.61B
1-day change-5.18%-5.26%
YTD return-34.84%-46.51%
1-year return-27.02%-45.28%
5-year return—+249.61%
P/E ratio (TTM)10.59—
Forward P/E64.87—
EPS (TTM)$1.66$-4.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$812.03M—
Revenue growth (YoY)+96.97%—
Net income (latest FY)$-68.09M$-177.04M
Operating margin5.56%—
Net margin-8.38%—
52-week high$36.50$151.02
52-week low$14.19$53.20
Distance from 52-week high-51.84%-64.67%
Analyst consensusbuystrong_buy
Avg. price target upside+94.71%+182.76%
Average volume4.61M1.25M
Shares outstanding286.78M48.93M
Employees1,846155
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CAI has outperformed CELC by 18.3 percentage points over the past year.

About Caris Life Sciences

CAI stock →

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms.

Health Care · Medical Specialities · 1,846 employees

About Celcuity

CELC stock →

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).

Health Care · Medical Specialities · 155 employees

CAI vs CELC FAQ

Which is bigger, Caris Life Sciences or Celcuity?

Caris Life Sciences (CAI) is larger, with a market capitalization of $5.04B compared with $2.61B for Celcuity (CELC).

Which stock has performed better over the past year, CAI or CELC?

CAI returned -27.02% over the past 12 months, compared with -45.28% for CELC (price return, excluding dividends). Past performance does not predict future results.

Are Caris Life Sciences and Celcuity in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons